Best treatments for gastrointestinal neoplasms
9 products may treat gastrointestinal neoplasms, spanning FDA drug classes such as her2/neu receptor antagonist, anthracycline topoisomerase inhibitor. The current highest-rated option is herceptin. Ranked below by our independent recall-safety rating (rated where FDA data exists) — not medical advice; always consult a professional.
Quick answer: Of the 9 drugs we list for gastrointestinal neoplasms, none are yet flagged as generics in our price data, spanning classes such as her2/neu receptor antagonist, anthracycline topoisomerase inhibitor. 6 of 9 carry a safety score, from 60 to 72 out of 100. They’re ranked by each drug’s FDA recall-safety record — not clinical effectiveness for gastrointestinal neoplasms — so confirm the right choice with your prescriber.
Top-rated picks for gastrointestinal neoplasms: 1. Herceptin · 2. Kanjinti · 3. Lutathera
| # | Drug | Rating | Type | Form | Class | Generic? | Pharmacy pays | |
|---|---|---|---|---|---|---|---|---|
| 1 | 72/100 | Prescription | Injectable | HER2/neu Receptor Antagonist | No data | — | View → | |
| 2 | 72/100 | Prescription | Injectable | — | No data | — | View → | |
| 3 | 72/100 | Prescription | Injectable | — | No data | — | View → | |
| 4 | 70/100 | Prescription | Injectable | HER2/neu Receptor Antagonist | No data | — | View → | |
| 5 | 64/100 | Prescription | Injectable | — | No data | — | View → | |
| 6 | 60/100 | Prescription | Injectable | — | No data | — | View → | |
| 7 | Not yet rated | Prescription | Injectable | Anthracycline Topoisomerase Inhibitor | No data | — | View → | |
| 8 | Not yet rated | Prescription | Injectable | Anthracycline Topoisomerase Inhibitor | No data | — | View → | |
| 9 | Not yet rated | Prescription | Injectable | — | No data | — | View → |
Narrow by drug class
Explore the class hubs: her2/neu receptor antagonist · anthracycline topoisomerase inhibitor
Full ranking · 9 treatments
herceptin
Boxed warningPrescriptionFDA-sourced
Herceptin (Trastuzumab) is a HER2/neu receptor antagonist used to treat Breast Neoplasms, Gastrointestinal Neoplasms, Stomach Neoplasms.
Price varies
kanjinti
Boxed warningPrescriptionFDA-sourced
Kanjinti (Trastuzumab-Anns) is a medication used to treat Breast Neoplasms, Gastrointestinal Neoplasms.
Price varies
lutathera
PrescriptionFDA-sourced
Lutathera (Lutetium Lu 177 Dotatate) is a medication used to treat Gastrointestinal Neoplasms, Pancreatic Neoplasms, Neuroendocrine Tumors.
Price varies
hercessi
PrescriptionFDA-sourced
Hercessi (Trastuzumab-Strf) is a HER2/neu receptor antagonist used to treat Breast Neoplasms, Gastrointestinal Neoplasms, Stomach Neoplasms.
Price varies
ogivri
Boxed warningPrescriptionFDA-sourced
Ogivri (Trastuzumab-Dkst) is a medication used to treat Breast Neoplasms, Gastrointestinal Neoplasms.
Price varies
trazimera
Boxed warningPrescriptionFDA-sourced
Trazimera (Trastuzumab-Qyyp) is a medication used to treat Breast Neoplasms, Gastrointestinal Neoplasms.
Price varies
Frequently asked
- What treats gastrointestinal neoplasms?
- Our catalog lists 9 products that may treat gastrointestinal neoplasms, based on NIH RxClass (MED-RT “may treat”) drug-classification data — not the verbatim FDA label. They're rated where FDA recall-safety data exists; the current top-rated option is herceptin.
- What is the best-rated treatment for gastrointestinal neoplasms?
- By our independent recall-safety rating — not an efficacy measure — herceptin ranks highest among the products we list for gastrointestinal neoplasms. Always consult a professional.
- How are these treatments ranked?
- By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.
- What types of drugs treat gastrointestinal neoplasms?
- Treatments for gastrointestinal neoplasms span FDA drug classes including her2/neu receptor antagonist, anthracycline topoisomerase inhibitor. Compare every option side by side, ranked by independent rating, above.
Treatment associations are derived from NIH RxClass (MED-RT “may treat”) drug-classification data — not the verbatim FDA label. This is general reference, not medical advice — always consult a licensed professional.
Where this ranking comes from
Our score is computed from public FDA data — not from opinion, sponsorship or user votes. How we rate.
- FDA Drug Enforcement (recall) database — the recall history behind the safety score
- DailyMed (NIH National Library of Medicine) — the FDA labels we quote for uses, dosing and warnings
- Drugs@FDA — approvals, strengths and marketing status